Stocks to Buy Today - Stock Message Board, Discussion Forum, Blog
Stemline Therapeutics stock will IPO on the NASDAQ this week under the ticker symbol STML. The Stemline Therapeutics (STML) IPO is expected to price between $11-$13 on 3.5 million shares. Stemline Therapeutics (STML) stock will be a hot biotech IPO that has the chance to do very well.
Stemline Therapeutics (STML) S-1 Filing
We are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk. We believe that we are developing the most clinically advanced pipeline of anti-CSC therapeutics and that we hold a broad portfolio of CSC-focused intellectual property, establishing us as a leader in the CSC field. Among the therapeutic candidates in our portfolio, we are currently developing two clinical-stage product candidates, SL-401 and SL-701, for which we hold global marketing rights. The lead indication for SL-401, a biologic targeted therapy (a therapy designed to preferentially target cancer cells), is acute myeloid leukemia, or AML. The lead indications for SL-701, a therapeutic cancer vaccine comprised of synthetic peptides that correspond to specific targets, called epitopes, on CSCs and tumor bulk of brain cancer, are pediatric and adult brain cancer. In completed Phase 1/2 clinical trials, both SL-401 and SL-701 have demonstrated single agent activity (activity as a stand-alone therapy), including instances of durable complete responses, or CRs, which is the disappearance of all signs of cancer in response to treatment. In addition, SL-401 and SL-701 have demonstrated a longer overall survival, or OS, in patients compared with that achieved in the past with traditional therapies. We plan to advance SL-401 into a registration-directed randomized Phase 2b clinical trial to treat adult relapsed or refractory AML patients who failed two previous treatments (i.e., third-line AML) with OS as the primary endpoint. A registration-directed trial is one designed to meet FDA expectations necessary for marketing approval. We plan to advance SL-701 into a pivotal Phase 2b clinical trial to treat pediatric patients with malignant glioma. In addition, we plan to advance SL-701 into a Phase 2b clinical trial in adult patients with glioblastoma, or GBM, who failed one previous treatment (i.e., second-line GBM). We have a proprietary discovery platform, StemScreen®, for the discovery of novel CSC-targeted compounds, from which we have discovered or validated several of our clinical and preclinical product candidates and which we believe may be instrumental in the discovery of additional new therapies targeting a wide range of cancer types.
More IPO's - http://www.stockstobuy.org/forum/topic/listForTag?tag=ipo